Besides direct inhibition of B‐cell lymphoma, downregulation of regulatory T‐cells and repolarization of CD4‐positive T‐cells from Th‐2 to Th‐1 has been observed during ibrutinib treatment for FL [6] and CLL [3]. The gene discussed is CD4; the disease is B-cell non-Hodgkin lymphoma.